Table 4.

Cost-impact analysis using response-guided therapy with sofosbuvir in combination of simeprevir, daclatasvir or ledipasvir.

HCV RNA <15 IU/ml [days]	n (%)	Therapy duration [weeks]	Projected outcome using response-guided therapy (RGT) n [outcome]	Estimated treatment cost saving (in France#) using RGT compared to standard 12 weeks of therapy [x1000€]	Estimated treatment cost saving using RGT compared to standard 12 weeks of therapy in 100 subjects
14	28(48%)	6	26* [SVR] + 2** [non-SVR]	698@	43%
28	23(40%)	10	23 [SVR]	223	17%
42	7(12%)	12	6 [SVR] + 1*** [non-SVR]	0&	0%
Total				921	16%

^*Assuming that the 3 and 1 patients who had HCV<15 at days 2 and 7, respectively, in which modeling could not be performed (Table 3), would have achieved cure with 6 weeks of therapy;

^**projected relapsers since modeling projected more than 6 weeks to reach cure (Table 3);

^***observed relapser in the current study;

^@Assuming extra cost to re-treat the 2 non-SVR with a 12 week course of dual therapy;

^&no difference since one patient was a relpaser;

^#Average cost (58,167€) of DAA therapy as in Table 3.